Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges

20262 citationsJournal Articlegreen Open Access

Authors

Aadia I. Rana · University of Alabama at Birmingham

Lu Zheng · Harvard University

Jose R. Castillo-Mancilla · University of Colorado Anschutz Medical Campus

Yajing Bao · Harvard University

Sara B. Sieczkarski · Frontier Science & Technology Research Foundation

Kristina M. Brooks · University of Colorado Anschutz Medical Campus

JE Lake ·

Abstract

Monthly injections of long-acting cabotegravir-rilpivirine were superior to standard oral ART in reducing the risk of regimen failure among persons with HIV who had adherence challenges. (Funded by the National Institute of Allergy and Infectious Diseases; LATITUDE ClinicalTrials.gov number, NCT03635788.).

Topics & Keywords

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 9, pp. 858-871

DOI: 10.1056/nejmoa2508228

Field-Weighted Citation Impact: 64.85